{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196506","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.508419+00:00","generated_at":"2026-05-31T11:07:15.758860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phathom Q2 revenue $7.3M, prescriptions up 184%; VOQUEZNA gets FDA approval for Non-Erosive GERD","bullets":["Net revenues $7.3M in Q2 2024 vs $1.9M in Q1 2024; no Q2 2023 revenue due to launch in late 2023.","Over 122,000 cumulative prescriptions written (184% increase from 43,000); over 60,000 filled (240% from 17,500).","FDA approved VOQUEZNA 10mg for Non-Erosive GERD on July 18; commercial coverage now >116M lives (77% of US commercial).","Net loss $91.4M; non-GAAP adjusted net loss $73.3M; SG&A rose to $75.9M on launch commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196506","json":"https://secwatch.observer/filing/0001193125-24-196506.json","markdown":"https://secwatch.observer/filing/0001193125-24-196506.md","text":"https://secwatch.observer/filing/0001193125-24-196506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524196506/0001193125-24-196506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312524196506/d834335d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:07:15.758860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}